Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Jane M. Grant-Kels MD, FAAD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · July 16, 2022

Predictors of Severity in Paradoxical Psoriasis Due to Biologic Therapies

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Dawn Davis MD

Journal of the American Academy of Dermatology

Predictors of Severity in Paradoxical Psoriasis from Biologic Therapies: A Systematic Review

J Am Acad Dermatol 2022 Jun 16;[EPub Ahead of Print], DO Croitoru, SG Brooks, N Nathanielsz, O Silverberg, I Nicolau, AM Drucker, M Silverberg, J Yeung, JJ Limacher, V Piguet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Predictors of Severity in Paradoxical Psoriasis Due to Biologic Therapies

Additional Info

Predictors of Severity in Paradoxical Psoriasis from Biologic Therapies: A Systematic Review

Further Reading

Assessing Skin Cancer Diagnosis Accuracy by Lesion Type, Physician Experience, and Examination Method

Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Recently Updated